Methods for preparing highly purified AAV vector formulations are provided. The highly pure AAV formulations described herein are superior for clinical use.

The present invention relates to a separation of viruses of an essentially spherical shape from viruses with a rod-like shape that are comprised in a sample, wherein the sample comprising the viruses is subjected to filtration.

The present invention relates to a separation of viruses of an essentially spherical shape from viruses with a rod-like shape that are comprised in a sample, wherein the sample comprising the viruses is subjected to filtration.

A reared colony of larval superworms (Zophobas morio) experienced the swift and unexplained death of about 90% of its population. From dead larvae, a high-abundance virus was isolated and identified as a novel densovirus, Zophobas morio black wasting virus (ZmBWV), by means of cryo-electron microscopy. Strains of this virus were sequenced and an engineered vaccine virus sequence was developed. The black wasting disease was replicated in larvae by inoculation with pathogenic strains of ZmBWV. Larvae were inoculated with a non-pathogenic strain as prophylaxis and later challenged by inoculation with a pathogenic strain. The larvae that received a non-pathogenic strain were protected from later disease and death but the larvae that received a saline solution were not. The invention provides methods and vaccine products to inhibit morbidity and mortality of ZmBWWV in darkling beetle larvae.

In one aspect, the present disclosure provides a method for producing various virus-derived construct plasmids from starting plasmids (for example, virus-derived construct plasmids of the present disclosure). In one embodiment, a method for producing virus-derived construct plasmids of the present disclosure includes a step of preparing a set of starting plasmids containing at least of a part of nucleic acid sequences required to construct a virus-derived construct, the set of starting plasmids including a set of corresponding alternative unit nucleic acids, and the set of corresponding alternative unit nucleic acids including at least one set of corresponding alternative unit nucleic acids containing different nucleic acid sequences; a step of treating the set of starting plasmids with a restriction enzyme and preparing a mixed solution containing cleaved alternative unit nucleic acid fragments; a step of ligating the cleaved alternative unit nucleic acid fragments to form an integrated nucleic acid; and a step of bringing the integrated nucleic acid into contact with a transformed organism to form virus-derived construct plasmids.

The present disclosure relates to the technical field of molecular biology, and in particular to an adeno-associated virus structural plasmid capable of improving adeno-associated virus titer, which is provided with a Rep gene expression cassette and a Cap gene expression cassette in sequence in the gene expression direction. The Rep gene expression cassette includes a rep gene regulated and transcribed by a first promoter, and a transcription termination signal fragment is arranged behind the rep gene; the Cap gene expression cassette includes a cap gene regulated and transcribed by a second promoter, wherein the first promoter includes any one of a P5 promoter, an RSV promoter, an MMTV promoter, a UBC promoter, and a U6 promoter, and the second promoter includes one or more of a CMV promoter, a CBh promoter, a CAG promoter, an EF1 promoter, and an SFFV promoter.